Anti-Diabetic. Endocrine gland that produces the peptide hormones insulin, glucagon, somatostatin. Exocrine gland that produces digestive enzymes.
|
|
- Marylou Banks
- 6 years ago
- Views:
Transcription
1 Anti-Diabetic The pancreas : Endocrine gland that produces the peptide hormones insulin, glucagon, somatostatin Exocrine gland that produces digestive enzymes. The peptide hormones are secreted from cells located in the islets of Langerhans (β cells produce insulin, α cells produce glucagon, and δ cells produce somatostatin). Hyperinsulinemia cause severe hypoglycemia. Diabetes mellitus can cause serious hyperglycemia. Complications: retinopathy, nephropathy, neuropathy, cardiovascular Administration of antidiabetic agents can prevent morbidity & reduce mortality. DIABETES MELLITUS: is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. fasting plasma glucose > 7.0 mmol/l, or plasma glucose> 11.1 mmol/l 2 hours after a meal caused by TYPES OF DM: insulin deficiency insulin resistance Type 1 diabetes (insulin dependent diabetes mellitus) IDDM Type 2 diabetes (non-insulin dependent diabetes mellitus) NIDDM Gestational diabetes 1
2 Diabetes due to other causes (e.g: genetic defects or medications). Gestational diabetes as carbohydrate intolerance with onset or first recognition during pregnancy. It is important to maintain adequate glycemic control during pregnancy. because uncontrolled gestational diabetes can lead to fetal macrosomia (abnormally large body) and shoulder dystocia (difficult delivery), as well as neonatal hypoglycemia. Diet, exercise, and/ or insulin administration are effective in this condition. A. Type 1 IDDM Classic symptoms of insulin deficiency (polydepsia, polyphagia, polyuria, weight loss). Require exogenous insulin to avoid the catabolic state & is c.c.c by hyperglycemia & life threatening ketoacidosis. The development & progression of neuropathy, nephropathy, & retinopathy are directly related to the extent of glycemic control. measured as blood levels of glucose &/or hemoglobin A1c [HbA1c]. Treatment: IDDM must rely on exogenous (injected) insulin to control hyperglycemia Avoid ketoacidosis Maintain acceptable levels of glycosylated hemoglobin (HbA1c). Bl. glucose concentrations as close to normal as possible Avoid long-term complications. 2
3 Continuous SC insulin infusion (insulin pump) is another method of insulin delivery. Other methods of insulin delivery, such as transdermal, buccal, & intranasal. B. Type 2 diabetes NIDDM is influenced by genetic factors, aging, obesity, peripheral insulin resistance, rather than by autoimmune processes or viruses The pancreas retains some β-cell fx, but variable insulin secretion is insufficient to maintain glucose homeostasis. Frequently accompanied by the lack of sensitivity of target organs to either endogenous or exogenous insulin. Resistance to insulin is considered to be a major cause of this type of diabetes. Treatment: Maintain bl. glucose concentrations within normal limits Prevent the development of long-term complications. Weight reduction, exercise, dietary modification decrease insulin resistance & correct the hyperglycemia. Most patients are dependent on pharmacologic intervention with oral glucose-lowering agents. As the disease progresses, β-cell Fx declines & insulin Rx required to achieve satisfactory S. glucose levels. SIGNS & SYMPTOMS OF DM Insulin deficiency causes hyperglycaemia leading to glycosuria Increased catabolism: Increased lipolysis(in adipose tissue) 3
4 Increased fatty acids (in plasma) Oxidation(in liver) Decreased anabolism: Osmotic diuresis Dehydration & loss of electrolytes (KETOACIDOSIS, DIABETIC COMA) TYPES OF DIABETES FEATURE TYPE1DM TYPE2 DM Frequency 10-20% 80-90% Age at onset Early (below 35) Late (after 40) Type of onset Abrupt and severe Gradual & insidious Weight Normal Obese HLA Linked to HLA DR3,4,DQ - Family history <20% About 60% Genetic locus - Chromosome 6 Pathogenesis Autoimmune destruction of B- pancreatic cells Insulin resistance Islet cell antibodies present - Decreased insulin Normal or increased insulin Clinical management Insulin & diet Diet,exercise,oral drugs,insulin Acute complications Ketoacidosis Hyperosmolar coma 4
5 INSULIN A polypeptide hormone with two peptide chains that are connected by disulfide bonds. Synthesized as a precursor (pro-insulin) that undergoes proteolytic cleavage to form insulin and C peptide, both of which are secreted by the ß cells of the pancreas triggered by high bl. glucose.. Insulin & glucagon regulate bl. glucose levels. ACTIONS : Metabolism, Actions on liver, muscle and fat. Conserves fuel by facilitating the uptake & storage of glucose, amino acids & fats after a meal Insulin secretion is regulated by: Bl.glucose levels Certain amino acids Other hormones Autonomic mediators. High blood glucose is taken up by the glucose transporter into the β cells of the pancreas. it is phosphorylated by glucokinase, which acts as a glucose sensor. The products of glucose metabolism enter the mitochondrial respiratory chain & generate adenosine triphosphate (ATP). The rise in ATP levels causes a block of K+ channels, leading to membrane depolarization and an influx of Ca2+. The increase in intracellular Ca2+ causes pulsatile insulin exocytosis. The sulfonylureas and glinides owe their hypoglycemic effect to the inhibition of K+ channels. 5
6 Sources of insulin: Human insulin is produced by recombinant DNA technology using special strains of Escherichia coli or yeast that have been genetically altered to contain the gene for human insulin. Modifications of the amino acid sequence of human insulin have produced insulins with different pharmacokinetic properties. e.g :Lispro, Aspart, Glulisine, have a faster onset & shorter duration of action than regular insulin, because they do not aggregate or form complexes. Glargine & Detemir : long-acting & prolonged, flat levels of the hormone following injection. M of Action: Acts on insulin receptors on liver cells,fat cells and stimulates glucose transport across membrane by ATP dependent transporters like GLUT 4 &GLUT 1 Insulin administration Insulin is a polypeptide, it is degraded in the GIT. Therefore, it is generally administered SC. In a hyperglycemic emergency, regular insulin is injected IV. Insulin preparations vary primarily in their onset of activity & in duration of activity. This is due to differences in the a.a sequences of the polypeptides. Dose, site of injection, blood supply, temperature, and physical activity can affect the duration of action of the various preparations. Insulin is inactivated by insulin-degrading enzyme (also called insulin protease ), which is found mainly in the liver and kidney. 6
7 Adverse reactions to insulin Hypoglycemia are the most serious & common adverse reactions to an excessive dose of insulin. Long term DM commonly do not produce adequate amounts of the counter-regulatory hormones (glucagon, epinephrine, cortisol, GH), which normally provide an effective defense against hypoglycemia. Other S E : weight gain, lipodystrophy (less common with human insulin), allergic reactions, local injection site reactions. INSULIN PREPARATIONS and TREATMENT A. Rapid-acting & short-acting insulin preparations 4 preparations: regular insulin, insulin lispro, insulin aspart, insulin glulisine. Regular insulin is a short-acting, soluble, crystalline zinc insulin, usually given Sc or IV in emergencies) It rapidly lowers bl. glucose. Regular insulin, insulin lispro, and insulin aspart are pregnancy category B Insulin glulisine is pregnancy category C. Insulin lispro differs from regular insulin in that lysine and proline at positions 28 and 29 in the B chain are reversed. This results in more rapid absorption after SC than is seen with regular insulin. Consequently, it acts more rapidly. Peak levels are seen at min after injection, as compared with min for regular insulin. It also has a shorter duration of activity. Insulin aspart and insulin glulisine have pharmacokinetic and pharmacodynamic properties similar to those of insulin lispro. 7
8 They are administered to mimic the prandial (mealtime) release of insulin, and they are usually not used alone but with a longeracting insulin to ensure proper glucose control. Like regular insulin, they are administered subcutaneously. B. Intermediate-acting insulin : Neutral protamine Hagedorn (NPH) insulin is a suspension of crystalline zinc insulin combined at neutral ph with a positively charged polypeptide, protamine Delayed absorption of the insulin because of its conjugation with protamine, forming a less-soluble complex 3.Long-acting insulin preparations : a. Insulin glargine b. Insulin detemir The length of time to onset is 3-4 hrs and the max duration is hrs. B. Intermediate-acting insulin (NPH) insulin : Another name is insulin isophane. Its duration of action is intermediate because of the delayed absorption from its conjugation with protamine, forming a lesssoluble complex. NPH insulin should only be given SC (Never IV) and is useful in treating all forms of DM except diabetic ketoacidosis and emergency hyperglycemia. It is used for basal control & is usually given along with rapid- or short-acting insulin for mealtime control. A similar compound called neutral protamine lispro NPL insulin has been prepared that is used only in combination with insulin lispro.] 8
9 C. Long-acting insulin preparations 1. Insulin glargine: Slower in onset than NPH insulin, flat, prolonged hypoglycemic effect with no peak. Like the other insulins, it must be given SC 2. Insulin detemir: Has a fatty-acid side chain. This addition enhances association to albumin. Slow dissociation from albumin results in long-acting properties similar to those of insulin glargine. Neither insulin detemir nor insulin glargine should be mixed in the same syringe with other insulins, because doing so may alter the pharmacodynamics and pharmacokinetic properties. D. Insulin combinations Various premixed combinations of human insulins, such as 70% NPH insulin + 30% regular insulin, 50 % of each of these, and 75% NPL insulin plus 25% insulin lispro, are also available. E. Standard treatment versus intensive treatment Standard injection of insulin 2x /d. Intensive treatment normalize bl glucose through more frequent injections of insulin 3 or > x /d in response to monitoring bl glucose levels). Target mean bl glucose level of 154 mg/dl or less with DM. The frequency of hypoglycemic episodes, coma, and seizures due to excessive insulin is higher with intensive treatment regimens. Regular Human Insulin A short-acting preparation 9
10 FDA approved to treat IDDM & NIDDM and for hyperglycemia during pregnancy. Administered SC as with other insulins (the only preparation that may be administered IM and IV) This insulin acts within minutes and lasts from 1-12hrs. Pharmacokinetics of Insulin Destroyed in the GIT, and must be given parentrally-usually SC, but IV or occasionally IM in emergencies Insulin should be administered mins prior to meal Insulin Delivery Devices INSULIN SYRINGES: Prefilled disposible syringes with regular or modified insulins PEN DEVICES: Fountain pen like :insulin cartridges INHALED INSULIN: Fine powder delivered through nebuliser,rapid absorption INSULIN PUMPS: Portable infusion devices connected to subcutaneously placed cannula(continuous insulin infusion) INSULIN PATCH-PEN: A small (two inches long, one inch wide and ¼ inch thick) plastic device is designed to be worn on the skin like a bandage IMPLANTABLE PUMPS: electromechanical mechanism regulates insulin delivery from percutaneously refillable reservoir Mechanical pumps, fluorocarbon propellants &osmotic pumps are also being developed OTHER ROUTES: Oral (liposome) 11
11 Rectal Nasal Intraperitoneal SYNTHETIC AMYLIN ANALOG Pramlintide Synthetic amylin analog (indicated as adjunct to mealtime insulin therapy with IDDM and NIDDM. By acting as an amylinomimetic Delays gastric emptying, decreases postprandial Glucagon secretion, improves satiety. Administered by SC injection and should be injected immediately prior to meals. When initiated, the dose of rapid- or short-acting insulin should be decreased by 50% prior to meals to avoid a risk of severe hypoglycemia. May not be mixed in the same syringe with any insulin preparation. S E: mainly GIT, nausea, anorexia, and vomiting. Alternative Medicine Medicinal plants have been studied for the treatment of diabetes, however there is insufficient evidence to determine their effectiveness e.g: Cinnamon Chromium supplements Vanadyl sulfate a salt of vanadium Thiamine 11
12 Oral hypoglycemic Oral hypoglycemic Agents Orally to reduce the bl glucose levels in NIDDM who cannot control by diet alone. DM after age 40 and have had DM less than 5 yrs are those most likely to respond well to oral glucose lowering agents. Long-standing disease may require a combination of glucoselowering drugs with or without insulin to control their hyperglycemia. Oral anti-diabetic drugs : Biguanides : Metformin Sulfonylureas: Glimepiride, Glyburide, Tolbutamide, Glibenclamide, Glipizide Meglitinides : Nateglinide, Repaglinide Thiazolidinediones : Pioglitazone, Rosiglitazone Alpha -glucosidase inhibitors: Acarbose, Miglitol A. Sulfonylureas Insulin secretagogues, because they promote insulin release from the β cells of the pancreas. The primary drugs used today are the secondgeneration drugs (Glyburide, Glipizide, and Glimepiride). Mechanism of action: 1) Stimulation of insulin release from the β cells of the pancreas by blocking the ATP-sensitive K+ channels, resulting in depolarization and Ca2+ influx 12
13 2) Reduction in hepatic glucose production 3) Increase in peripheral insulin sensitivity. Pharmacokinetics : Orally, drugs bind to serum proteins, metabolized by the liver, excreted by the liver or kidney. The duration of action ranges from hours. Adverse effects: Weight gain, hyperinsulinemia, hypoglycemia. should be used with caution in patients with hepatic or renal insufficiency (accumulation= hypoglycemia. Renal impairment is a particular problem in the case of those agents that are metabolized to active compounds such as Glyburide. Glyburide has minimal transfer across the placenta and may be a reasonably safe alternative to insulin therapy for diabetes in pregnancy. Sulfonylureas 1 st gen : Tolbutamide and Chlorpropamide 2 nd gen : Glibenclamide, Glipizide, Glimperide MOA : Acts on B cells stimulating insulin secretion and thus reducing plasma glucose Tolbutamide : half-life : 6-12 hrs Pharmacokinetics : Orally, Some converted in liver to weakly active hydroxytolbutamide, some carboxylated to inactive compound. Renal excretion. Side Effects: Hypoglycaemia. 13
14 May decrease iodide uptake by thyroid. Contraindicated in liver failure, renal failure Glibenclamide : half life : hrs Pharmacokinetics : Orally, Some is oxidised in the liver to moderately active products, excreted in urine; 50% is excreted unchanged in the faeces. Side Effects: May cause hypoglycaemia. The active metabolite accumulates in renal failure. Glipizide : half-life : hrs Pharmacokinetics: Peak plasma levels in 1 hour. Most is metabolised in the liver to inactive products, which are excreted in urine; 12% is excreted in faeces. SideEffects Causes hypoglycaemia, has diuretic action Most sulfonylureas cross the placenta and enter breast milk; as a result, use of sulfonylureas is contraindicated in pregnancy and in breast feeding Drug interactions: NSAIDs, MAOI, anti bacterials, anti fungals B. Meglitinides (Glinides) Repaglinide and Nateglinide. Like sulfonylureas, they have common actions. Mechanism of action: dependent on functioning pancreatic β cells. They bind to a distinct site on the sulfonylurea receptor of ATP sensitive potassium channels, thereby initiating a series of reactions culminating in the release of insulin. However, in contrast to the 14
15 sulfonylureas, they have a rapid onset and a short duration. They are particularly effective in the early release of insulin that occurs after a meal and are categorized as postprandial glucose regulators. Pharmacokinetics : well absorbed orally. Both Glinides are metabolized to inactive products by cytochrome P450 3A4 in the liver and are excreted through the bile. Adverse effects: can cause hypoglycemia, the incidence of this adverse effect appears to be lower than that with the sulfonylureas. Repaglinide (Reported to cause severe hypoglycemia in those who taking the lipid-lowering drug Gemfibrozil : (the lipid-lowering drug) Concurrent use is contraindicated. Weight gain is less of a problem with the Glinides than with the sulfonylureas. These agents must be used with caution in patients with hepatic impairment. Meglitinides Act like the sulfonylureas, but they don t have sulfonylurea moiety. Include Repaglinide and Nateglinide MOA : Same as sulfonylureas. Short duration of action, low risk of hypoglycaemia. Given orally, rapidly metabolized by liver enzymes 15
16 Oral antidiabetic drugs are of value only in the treatment of type 2 (NIDDM) whose condition cannot be controlled by diet alone. May also be used with insulin in the management DM Use of an oral antidiabetic drug with insulin may decrease the insulin dosage in some individuals. C: Biguanides Metformin: It does not cause hypoglycaemia MOA: Increase glucose uptake + utilisation in skeletal muscle (thereby reducing insulin resistance) and reduce hepatic glucose production (gluconeogenesis). Pharmacokinetic: Metformin :half-life of about 3 hours and is excreted unchanged in the urine. Oral agents : Insuline sensitizers 2 classes of oral agents, the Biguanides and Thiazolidinediones, improve insulin action. These agents lower blood sugar by improving target-cell response to insulin without increasing pancreatic insulin secretion. Metformin Classed as an insulin sensitizer. increases glucose uptake and use by target tissues, thereby decreasing insulin resistance. Metformin differs from the sulfonylureas in that it does not promote insulin secretion. Therefore, the risk of hypoglycemia is far less than that with sulfonylurea agents. 16
17 MOA: The main mechanism is reduction of hepatic glucose output, largely by inhibiting hepatic gluconeogenesis. Metformin also slows intestinal absorption of sugars and improves peripheral glucose uptake and utilization. An important property of this drug is its ability to reduce hyperlipidemia. Metformin as the drug of choice for newly diagnosed type 2 DM. Metformin may be used alone or in combination with one of the other agents as well as with insulin. Pharmacokinetics: Metformin is well absorbed orally, is not bound to serum proteins, and is not metabolized. Excretion is via the urine. Adverse effects: Largely gastrointestinal. Metformin is contraindicated in DM + renal and/or hepatic disease and in those with diabetic ketoacidosis (DKA). Should be discontinued in cases of acute MI, exacerbation of CHF, severe infection. Metformin should be used with caution in older than age 80 years and in those with a Hx of CHF or alcohol abuse. Should be temporarily discontinued in patients undergoing diagnosis requiring IV radiographic contrast agents. Rarely, potentially fatal lactic acidosis has occurred. Long-term use may interfere with vitamin B12 absorption. 17
18 Other uses: In addition to the treatment of type 2 DM Metformin is effective in the treatment of polycystic ovary disease. Its ability to lower insulin resistance in these women can result in ovulation and, therefore, possibly pregnancy. Side effects: Dose-related gastrointestinal disturbances Lactic acidosis is a rare but potentially fatal toxic effect Long-term use may interfere with absorption of vitamin B 12 Contraindications: Metformin should not be given in Renal failure Hepatic disease Hypoxic pulmonary disease Heart failure or shock D: Thiazolidinediones (Glitazones) Insulin sensitizers (TZDs) or also called the Glitazones. Although insulin is required for their action, these drugs do not promote its release from the pancreatic β cells, so hyperinsulinemia is not a risk. Troglitazone was the first of these to be approved for the treatment of type 2 DM but was withdrawn after a number of deaths from hepatotoxicity were reported. The two members of this class currently available are Pioglitazone and Rosiglitazone. Glitazones 18
19 MOA : Bind to a nuclear receptor called the peroxisome proliferatoractivated receptor-γ (PPARγ), which is complexed with retinoid X receptor (RXR). PPARγ-RXR complex bind to DNA, promoting transcription of several genes with products that are important in insulin signalling. Pharmacokinetics : Orally high plasma protein bound, peak plasma concentration-within 2 hrs Metabolized by liver enzymes. Rosiglitazone metabolites in urine Pioglitazone metabolites in bile Side effects : Weight gain Fluid retention, headache, fatigue and gastrointestinal disturbances. Thiazolidinediones are contraindicated in pregnant or breastfeeding women and in children. E: α-glucosidase inhibitors Acarbose : An inhibitor of intestinal α-glucosidase, is used in type 2 DM. MOA : Delays CHO absorption, reducing the postprandial increase in blood glucose. Side effects: 19
20 flatulence, loose stools or diarrhoea, and abdominal pain and bloating. Like Metformin, it may be particularly helpful in obese type 2 DM, and it can be co-administered with Metformin. PEPTIDE ANALOGS RECENT DRUGS Injectable Incretin mimetics (insulin secretagogues) Molecules that fulfill criteria for being an incretin are glucagonlike peptide-1 (GLP-1) and gastric inhibitory peptide (glucosedependent insulinotropic peptide, GIP) Both GLP-1 and GIP are rapidly inactivated by enzyme dipeptidyl peptidase-4 (DPP-4). Exenatide (first GLP-1 agonist) Liraglutide (a once-daily) Taspoglutide Side-effects: Decreased gastric motility Nausea weight loss DIPEPTIDYL PEPTIDASE-4 INHIBITORS (DPPI) Increase blood concentration of the incretin GLP-1 by inhibiting its degradation by dipeptidyl peptidase-4. Vildagliptin (Galvus) EU Approved 2008 Sitagliptin (Januvia) FDA approved Oct 2006 Saxagliptin (Onglyza) FDA Approved July
21 Linagliptin (Tradjenta) FDA Approved May 2, 2011 DPP-4 inhibitors lowered haemoglobin A1C values by 0.74%, comparable to other anti-diabetic drugs. Mixed meal Intestinal GLP-1 release GLP-1 GLP-1 (7-36) active DPP-4 DPP-4 inhibitor GLP-1 inactive Sitagliptin : Well absorbed through GIT 80% excreted unchanged in urine half-life :8-14 hours Injectable Amylin analogues Pramlintide Slow gastric emptying Suppress glucagon. (the only clinically available amylin analogue: administered by SCinjection) Typical reductions in A1C values are %. Adverse effect :nausea 21
22 22
Drugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationDiabetes Mellitus. Raja Nursing Instructor. Acknowledgement: Badil 09/03/2016
Diabetes Mellitus Raja Nursing Instructor 09/03/2016 Acknowledgement: Badil Objective: Define Diabetes Mellitus (DM) & types of DM. Understand the pathophysiology of Type-I & II DM. List the clinical features
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationXultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow
Xultophy 100/3.6 (insulin degludec, liraglutide) New Product Slideshow Introduction Brand name: Xultophy Generic name: Insulin degludec, liraglutide Pharmacological class: Human insulin analog + glucagon-like
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationBY Y. Chandravadana Associate proffesor Krishna teja pharmacy college Tirupati.
BY Y. Chandravadana Associate proffesor Krishna teja pharmacy college Tirupati. DEFINITION : A syndrome of disordered metabolism due to a combination of hereditary and environmental causes. CLASSIFICATION:
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationEndo 2 SLO Practice (online) Page 1 of 7
Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationDiabetes Mellitus. Diabetes Mellitus. Insulin. Glucose. Classifications of DM. Other glucose regulating Hormones
Diabetes Mellitus Diabetes Mellitus Pathophysiology Literally sweet urine Defined by excess blood serum glucose Normally all glucose in the PCT is reabsorbed by active transport When blood glucose is elevated,
More informationOral and Injectable Medication Options for Diabetes Treatment
Oral and Injectable Medication Options for Diabetes Treatment Presented by: Dr. Daphne E. Smith, Pharm.D., CDE Clinical Assistant Professor/Clinical Pharmacist-University of Illinois at Chicago College
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationDiabetes(Mellitus( Dr(Kawa(A.(Obeid( PhD!Therapeutics!
DiabetesMellitus DrKawaA.Obeid PhDTherapeutics 1 Definitionandabriefintroduction Diabetes mellitus is the most common of the endocrine disorders. It is primarily a disorder of carbohydratemetabolismcharacterisedbyhyperglycaemia,thisisduetoimpairedinsulinsecretion
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationassociated with serious complications, but reduce occurrences with preventive measures
Wk 9. Management of Clients with Diabetes Mellitus 1. Diabetes Mellitus body s inability to metabolize carbohydrates, fats, proteins hyperglycemia associated with serious complications, but reduce occurrences
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationHistory of Investigation
Acini - Pancreatic juice (1º) (2º) Secretions- neuronal and hormonal mechanisms 1) Secretin - bicarbonate rich 2) Cholecystokinin - enzyme rich Islets of Langerhans (contain 4 cell types) Alpha cells (α)-
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationINSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.
INSULIN OVERVIEW Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro Humalog 15-30 min 30-90 min 3-5 hrs aspart glulisine Short-Acting Regular insulin NovoLog Apidra
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More information第十五章. Diabetes Mellitus
Diabetes-1/9 第十五章 Diabetes Mellitus 陳曉蓮醫師 2/9 - Diabetes 羅東博愛醫院 Management of Diabetes mellitus A. DEFINITION OF DIABETES MELLITUS Diabetes Mellitus is characterized by chronic hyperglycemia with disturbances
More informationDiabetes Mellitus. Intended Learning Objectives:
Intended Learning Objectives: Diabetes Mellitus 1. Compare and contrast the differences between the drug therapy recommendations of several of the latest and leading diabetes guidelines. 2. Assess the
More informationHormonal Regulations Of Glucose Metabolism & DM
Hormonal Regulations Of Glucose Metabolism & DM What Hormones Regulate Metabolism? What Hormones Regulate Metabolism? Insulin Glucagon Thyroid hormones Cortisol Epinephrine Most regulation occurs in order
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationSoliqua 100/33. (insulin glargine, lixisenatide) New Product Slideshow
Soliqua 100/33 (insulin glargine, lixisenatide) New Product Slideshow Introduction Brand name: Soliqua 100/33 Generic name: Insulin glargine (rdna origin), lixisenatide Pharmacological class: Human insulin
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationNormal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),
Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), in which blood glucose predominantly originates from
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationVICTOSA and Renal impairment DR.R.S.SAJAD
VICTOSA and Renal impairment DR.R.S.SAJAD February 2019 Main effect of GLP-1 is : Stimulating glucose dependent insulin release from the pancreatic islets. Slow gastric emptying Inhibit inappropriate
More informationDiabetes Medications: Oral Anti-Hyperglycemic Medications
Diabetes Medications: Oral Anti-Hyperglycemic Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6.
More informationMetformin Hydrochloride
Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More information18. PANCREATIC FUNCTION AND METABOLISM. Pancreatic secretions ISLETS OF LANGERHANS. Insulin
18. PANCREATIC FUNCTION AND METABOLISM ISLETS OF LANGERHANS Some pancreatic functions have already been discussed in the digestion section. In this one, the emphasis will be placed on the endocrine function
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More information22 Emerging Therapies for
22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationIntroduction and literature review
1. NEED FOR THE STUDY Accumulation of lipids in diabetes is mediated through specially deficiency hence, diabetic patient more prone to hypertriglyceridaemia and hypercholesterolaemia (Kasiappan et al.,2005).
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More informationUnderstanding Diabetes and Insulin Delivery Systems
Page 1 This program has been supported by an educational grant from Sanofi Aventis Scott K. Stolte, Pharm.D. Associate Dean, Academic Affairs Bernard J. Dunn School of Pharmacy Shenandoah University Winchester,
More informationPathogenesis of Diabetes Mellitus
Pathogenesis of Diabetes Mellitus Young-Bum Kim, Ph.D. Associate Professor of Medicine Harvard Medical School Definition of Diabetes Mellitus a group of metabolic diseases characterized by hyperglycemia
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationMaking Sense of Mediations for Diabetes
Making Sense of Mediations for Diabetes Lisa Kroon, PharmD, CDE Professor of Clinical Pharmacy UCSF School of Pharmacy Diabetes Mellitus: U.S. Impact Source: ADA; released June 10, 2014 ~1-1.5 Million
More informationDiabetes Mellitus (Do we really know what s going on?)
Diabetes Mellitus (Do we really know what s going on?) Chris Willis-Mahn, DVM, DACVIM (SAIM), DACVN GSLVMA 11.13.2018 Affiliated with: Diabetic Types DOGS Type 1 Idiopathic Immune-mediated? Type 2 Rare
More informationPharmacological Treatments for Type 2 Diabetes
Chapter 20 Pharmacological Treatments for Type 2 Diabetes Roberto Pontarolo, Andréia Cristina Conegero Sanches, Astrid Wiens, Helena Hiemisch Lobo Borba, Luana Lenzi and Suelem Tavares da Silva Penteado
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationInternational Journal of Allied Medical Sciences and Clinical Research (IJAMSCR)
International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR) IJAMSCR Volume 3 Issue 1 Jan-Mar- 2015 www.ijamscr.com Research article Medical research Diabetes mellitus associated mortality:
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationSupplementary Online Content
Supplementary Online Content Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Internal
More informationDiabetes Mellitus Type 2
Diabetes Mellitus Type 2 Objectives: Scope of diabetes Making the diagnosis Pathophysiology Disease consequences Management Conclusion Team Members: Allulu Alsulayhim, Hamad Alkhudhairy, Fahad Alzahrani,
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationInsulin analogues Das PP, Datta PG
The ORION Medical Journal 2007 Sep;28:497-500 Insulin analogues Das PP, Datta PG Introduction Diabetes mellitus is a very big challenge for our medical science. To overcome this problem we need newer generation
More informationWeek 3 The Pancreas: Pancreatic ph buffering:
Week 3 The Pancreas: A gland with both endocrine (secretion of substances into the bloodstream) & exocrine (secretion of substances to the outside of the body or another surface within the body) functions
More informationTherapy of Diabetes Mellitus
2016 edition by Jayne S. Reuben, PhD Department of Biomedical Sciences University of South Carolina School of Medicine Greenville Originally developed by Elliott Chideckel, MD Department of Medicine Robert
More information